China Universal Asset Management Co. Ltd. Has $401,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

China Universal Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 72.4% in the 3rd quarter, Holdings Channel reports. The fund owned 19,537 shares of the company’s stock after purchasing an additional 8,204 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $401,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NTLA. Vanguard Group Inc. lifted its position in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares in the last quarter. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 5.5% in the 2nd quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after buying an additional 606,507 shares during the period. Federated Hermes Inc. lifted its position in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after buying an additional 371,189 shares in the last quarter. Opaleye Management Inc. lifted its position in Intellia Therapeutics by 157.6% in the 1st quarter. Opaleye Management Inc. now owns 255,000 shares of the company’s stock worth $7,015,000 after buying an additional 156,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after buying an additional 98,865 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on NTLA shares. JPMorgan Chase & Co. dropped their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Citigroup cut their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus lowered their price target on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Robert W. Baird cut their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $59.13.

Intellia Therapeutics Trading Down 4.4 %

NTLA opened at $14.33 on Thursday. The business has a 50 day moving average of $20.40 and a 200-day moving average of $22.59. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -2.61 and a beta of 1.76. Intellia Therapeutics, Inc. has a 1-year low of $14.28 and a 1-year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. During the same period in the previous year, the business posted ($1.40) earnings per share. Intellia Therapeutics’s revenue for the quarter was down 48.5% on a year-over-year basis. Equities analysts predict that Intellia Therapeutics, Inc. will post -5.22 EPS for the current year.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.20% of the stock is owned by company insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.